Betalin Therapeutics

Company Overview

Snapshot

Founded in July 2015 by Shuki Joshua Hershcovich and Shay Hershcovich, Betalin Therapeutics operates with 1–10 employees. The company has raised $11.06 million across 6 funding rounds from 3 investors. In February 2024, Betalin Therapeutics secured funding from Together We Invest.

Business overview

Betalin Therapeutics is a Health Tech & Life Sciences company focused on developing an alternative to insulin injections and glucose testing for diabetes patients. Its core product, the Engineered Micro Pancreas (EMP), utilizes tissue engineering to create connective tissue that enables the body's beta cells to function properly and produce adequate insulin. The company operates within the Pharma & Medical Biotechnology sector, specifically in Biomaterials & Tissue Engineering, and serves global markets, targeting both healthcare providers and patients.

Strategic signal

In July 2023, Betalin Therapeutics made progress on its micro pancreas technology, signaling significant advancements in the treatment of Type 1 diabetes. This development indicates a potential shift in chronic disease management, offering investors a view into the company's immediate forward trajectory in bringing a novel therapeutic solution to market.

Company Intelligence Q&A

What is Betalin Therapeutics' primary product?

Betalin Therapeutics' primary product is the Engineered Micro Pancreas (EMP), designed to eliminate the need for insulin injections and glucose testing in diabetes patients by enabling the body's beta cells to function properly and produce insulin.

When was Betalin Therapeutics founded and by whom?

Betalin Therapeutics was founded in July 2015 by Shuki Joshua Hershcovich and Shay Hershcovich.

What is Betalin Therapeutics' core technology?

Betalin Therapeutics' core technology involves biomaterials and tissue engineering, specifically utilizing implants and cells to create the Engineered Micro Pancreas (EMP).

What significant progress has Betalin Therapeutics made in treating Type 1 diabetes?

In July 2023, Betalin Therapeutics reported progress on its micro pancreas technology, aiming to revolutionize Type 1 diabetes treatment.

Has Betalin Therapeutics received any grants from the European Union?

In January 2021 and September 2020, Betalin Therapeutics received grants from EU Horizon 2020.